...and a thorough ripping it was.

Kyle, If you simply look forward to the lack of cash outflow due research on development on the JZP meds and the inflow from Luvoz and Xyrem sales, in the next qtr alone, you get a big plus to the bottom line as the sales channels for those two drugs expand.

Should another company enter the equation as a partner, that possesses a much larger sales force, those number's grow even larger due to royalties. Throw in any buy in money from a partner and that's a one time benefit, even before additional drugs hit the pipeline.

I don't like to speculate because it effect objectivity but when your growing any business with huge potential, you get the looks from those who see potential.